Sign inJoin waitlistJoin the waitlist

Ari Grinspan

Director of the GI Microbial Therapeutics · Icahn School of Medicine at Mount Sinai

Credentials: · · · ·

History

Stony Brook Medicine
Present
Icahn School of Medicine at Mount Sinai
Present

Mount Sinai Hospital
2011–2014
New York Presbyterian Hospital-Weill Cornell
Chief ResidentUntil 2010
2008–2011
Albert Einstein College of Medicine
2004–2008
University of Pennsylvania
2004

Research

Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice
Immunity · 2019 · 450 citations
Interactions Between Diet and the Intestinal Microbiota Alter Intestinal Permeability and Colitis Severity in Mice
Gastroenterology · 2018 · 298 citations
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
Gastroenterology · 2021 · 176 citations

Jean-Frederic Colombel
11 papers
Yuying Luo
9 papers · 9 as a fellow
CK
Colleen Kelly
8 papers
Jessica Allegretti
8 papers
MD
Marla Dubinsky
8 papers
Monika Fischer
7 papers
Bruce Sands
5 papers
Eduardo Contijoch
5 papers · 1 as a resident
ZK
Zain Kassam
5 papers
ET
Emily Tixier
4 papers · 3 as a resident
Robert Hirten
4 papers · 4 as a fellow
Ryan Ungaro
4 papers

Grants

Comparison of Defined Live Biotherapeutic Product and Fecal Microbiota Transplantation for Treatment of Recurrent Clostridioides Difficile Infection
National Institute of Diabetes and Digestive and Kidney Diseases · R01
PI · $1M · Icahn School of Medicine at Mount Sinai
2022–2026

Clinical trials

MTC Versus FMT in for RCDI
Principal investigator · Completed · Phase 1
Icahn School of Medicine at Mount Sinai
2024–2025
Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)
Principal investigator · Terminated · Early phase 1
Ari M Grinspan
2021–2022
Fecal Microbiota Transplant National Registry
Site PI · Recruiting
American Gastroenterological Association
2017–2027